XT
SCNI

XTX Topco’s Scinai Immunotherapeutics SCNI Stock Holding History

XTX Topco’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24K Sell
1,676
-728
-30% -$3.58K ﹤0.01% 4079
2026
Q1 		$13.3K Sell
2,404
-325
-12% -$2.62K ﹤0.01% 3639
2025
Q4 		$19.4K Buy
+2,729
New +$31.1K ﹤0.01% 3065

Other funds holding SCNI

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

XTX Topco's SCNI Position: Q2 2026 in Review

XTX Topco reduced its Scinai Immunotherapeutics (SCNI) stake by 30% in Q2 2026, selling an estimated $3.58K and leaving 1,676 shares worth $4.24K. The position accounts for ﹤0.01% of the portfolio, ranked #4079.

XTX Topco first reported a position in SCNI in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.4K in Q4 2025. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

  • XTX Topco held 1,676 shares of Scinai Immunotherapeutics worth $4.24K as of Q2 2026.
  • XTX Topco sold 728 Scinai Immunotherapeutics shares in Q2 2026, an estimated $3.58K.
  • Scinai Immunotherapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #4079 holding.
  • XTX Topco first reported a position in Scinai Immunotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • XTX Topco's Scinai Immunotherapeutics position peaked at $19.4K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.